Syndax Pharmaceuticals, Inc. (SNDX)
NASDAQ: SNDX · Real-Time Price · USD
15.83
-0.96 (-5.72%)
At close: Nov 15, 2024, 4:00 PM
16.00
+0.17 (1.07%)
After-hours: Nov 15, 2024, 7:59 PM EST
Syndax Pharmaceuticals Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 |
| Revenue | 16 | - | - | 139.71 | 1.52 | 1.52 | |
| Revenue Growth (YoY) | - | - | - | 9109.56% | 0% | 0% | |
| Gross Profit | -48.19 | - | - | 139.71 | 1.52 | 1.52 | |
| Selling, General & Admin | 105.97 | 66.92 | 33.26 | 25.24 | 22.51 | 16.06 | |
| Research & Development | 167.05 | 163.03 | 118.5 | 88.25 | 50.44 | 42.99 | |
| Operating Expenses | 273.02 | 229.95 | 151.76 | 113.49 | 72.94 | 59.06 | |
| Operating Income | -321.21 | -229.95 | -151.76 | 26.22 | -71.42 | -57.54 | |
| Interest Expense | -0.19 | -0.21 | -3.14 | -1.9 | -2.36 | - | |
| Interest & Investment Income | 24.53 | 21.16 | 5.87 | 0.4 | 0.84 | 1.57 | |
| Other Non Operating Income (Expenses) | -0.2 | -0.36 | -0.32 | 0.2 | -0.22 | -0.08 | |
| EBT Excluding Unusual Items | -297.06 | -209.36 | -149.34 | 24.93 | -73.16 | -56.05 | |
| Pretax Income | -297.06 | -209.36 | -149.34 | 24.93 | -73.16 | -56.05 | |
| Net Income | -297.06 | -209.36 | -149.34 | 24.93 | -73.16 | -56.05 | |
| Preferred Dividends & Other Adjustments | - | - | - | - | 3.91 | - | |
| Net Income to Common | -297.06 | -209.36 | -149.34 | 24.93 | -77.06 | -56.05 | |
| Shares Outstanding (Basic) | 82 | 70 | 61 | 52 | 41 | 30 | |
| Shares Outstanding (Diluted) | 82 | 70 | 61 | 54 | 41 | 30 | |
| Shares Change (YoY) | 20.69% | 15.82% | 13.31% | 29.81% | 35.48% | 20.18% | |
| EPS (Basic) | -3.62 | -2.98 | -2.46 | 0.48 | -1.87 | -1.84 | |
| EPS (Diluted) | -3.62 | -2.98 | -2.46 | 0.46 | -1.87 | -1.84 | |
| Free Cash Flow | -258.86 | -160.6 | -133.68 | 29 | -71.26 | -50.61 | |
| Free Cash Flow Per Share | -3.15 | -2.28 | -2.20 | 0.54 | -1.73 | -1.66 | |
| Gross Margin | - | - | - | 100.00% | 100.00% | 100.00% | |
| Operating Margin | -2007.57% | - | - | 18.77% | -4708.17% | -3792.95% | |
| Profit Margin | -1856.64% | - | - | 17.84% | -5080.03% | -3694.59% | |
| Free Cash Flow Margin | -1617.90% | - | - | 20.76% | -4697.43% | -3336.32% | |
| EBITDA | -321.2 | -229.94 | -151.72 | 26.26 | -71.33 | -57.45 | |
| EBITDA Margin | - | - | - | 18.80% | - | - | |
| D&A For EBITDA | 0.01 | 0.01 | 0.03 | 0.04 | 0.09 | 0.09 | |
| EBIT | -321.21 | -229.95 | -151.76 | 26.22 | -71.42 | -57.54 | |
| EBIT Margin | - | - | - | 18.77% | - | - | |
| Revenue as Reported | 16 | - | - | 139.71 | 1.52 | 1.52 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.